Adendra Therapeutics
Translating dendritic cell biology into new therapies for cancer and autoimmunity.
Translating dendritic cell biology into new therapies for cancer and autoimmunity.
Adendra Therapeutics is an emerging biotechnology company focusing on translating dendritic cell biology into new therapies for cancer and autoimmunity. The company, founded in 2021, is dedicated to discovering and developing new small molecule and biologic medicines for the treatment of a wide range of cancers and autoimmune diseases.
Headquartered in the United Kingdom, Adendra Therapeutics recently secured a significant £40.00M Series A investment on 07 December 2021, with the funding coming from Apple Tree Partners. This capital injection is poised to propel the company's innovative research and development efforts aimed at addressing the unmet medical needs in the biopharma, biotechnology, and healthcare sectors.
For more information about Adendra Therapeutics, please visit their website at www.adendratx.com.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | £40.00M | 1 |
|
07 Dec 2021 |
No recent news or press coverage available for Adendra Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
